Sixteen trials of 5 agents of HIF-PHIs reported vascular-access
complications of HIF-PHIs for DD CKD anemia, containing 13,915
participants[2, 12, 16, 26, 27, 29-32, 35, 36, 38-40]. Compared with
ESAs, Daprodustat performed much better in the risk of vascular-access
complication (RR: 0.78, 95% CI: 0.66-0.92, p<0.01,
I2=0.3%), while Roxadustat performed a little worse
(RR: 1.15, 95% CI: 1.04-1.27, p<0.01, I2=0.3%). The
pooled results showed no significant difference in Enarodustat,
Vadadustat, and Molidustat (Figure 4).